Cancer Research Horizons is a brand-new company record, and its full research profile isn't ready yet.
cancerresearchhorizons.comCrawled Oct 26, 2026
The Cancer Research Horizons-AstraZeneca Functional Genomics Centre delivers pooled CRISPR screens to identify and validate new drug targets and approaches.
GammaDelta Therapeutics was founded in 2016 by Abingworth with support from Cancer Research Horizons, based on research by Professor Adrian Hayday and Dr Oliver Nussbaumer on γδ T cells.
The company’s portfolio covers drug discovery and development, from target identification to licensable opportunities.
The company supports research that benefits society by helping turn ideas into patient-focused progress.
The page highlights how research moves from lab to clinical application through stories from scientists, dealmakers, and policy influencers.
With an initial investment of £28m in resource and funding from LifeArc and Cancer Research UK, the consortium will bring together researchers, clinicians, scientists and industry to provide support, finance and expertise to progress innovations for children and young people’s cancers.
Cancer Research Horizons and AstraZeneca renewed their partnership for the Functional Genomics Centre, which will relocate to AstraZeneca’s Discovery Centre in Cambridge.
The page features news, publications, and events from the company’s network.
The company builds a community of business leaders whose philanthropy and expertise strengthen early-stage cancer ventures.
The company is led by experts in drug discovery and commercialization.
The expert network offers technical advice, management support, commercial expertise, and mentorship to founding teams and the wider portfolio.
Experts accelerate scientific breakthroughs to deliver patient benefits.
The company advances cutting-edge innovations into treatments and diagnostics for cancer patients.
The company invests in societal progress and supports entrepreneurs turning ideas into businesses.
The page describes the company’s impact on people affected by cancer.
Cancer Research Horizons partners across the fields of academia, industry, drug discovery and investors.
The company specializes in drug discovery, development, and commercialization, advancing lab innovations into cancer treatments and diagnostics.